Home » Stocks » Vericel

Vericel Corporation (VCEL)

Stock Price: $15.74 USD 0.57 (3.76%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 707.72M
Revenue (ttm) 122.72M
Net Income (ttm) -3,000
Shares Out 45.11M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE 500.00
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $15.74
Previous Close $15.17
Change ($) 0.57
Change (%) 3.76%
Day's Open 15.20
Day's Range 14.94 - 15.85
Day's Volume 630,264
52-Week Range 6.78 - 19.57

More Stats

Market Cap 707.72M
Enterprise Value 653.29M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.11M
Float 35.70M
EPS (basic) 0.02
EPS (diluted) 0.00
FCF / Share 0.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.43%
Payout Ratio n/a
Shares Short 6.47M
Short Ratio 9.07
Short % of Float 14.09%
Beta 2.96
PE Ratio n/a
Forward PE 500.00
P/FCF Ratio 69.87
PS Ratio 5.77
PB Ratio 6.50
Revenue 122.72M
Operating Income -1.13M
Net Income -3,000
Free Cash Flow 10.13M
Net Cash 54.43M
Net Cash / Share 1.21
Gross Margin 65.42%
Operating Margin -0.92%
Profit Margin n/a
FCF Margin 8.25%
ROA -5.56%
ROE -10.80%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$23.40*
(48.67% upside)
Low
20.0
Current: $15.74
High
32.0
Target: 23.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11890.8663.9254.3851.1728.800.020.020.020.09
Revenue Growth29.71%42.13%17.54%6.28%77.69%151457.89%-9.52%16.67%-79.78%-
Gross Profit80.2858.7033.5726.0824.7011.500.020.020.010.06
Operating Income-11.25-3.91-14.98-19.25-16.67-23.53-20.96-33.76-29.04-17.80
Net Income-9.67-8.14-17.29-19.57-16.34-19.92-15.62-29.47-19.67-14.56
Shares Outstanding44.1840.2433.3623.0923.7611.643.022.061.931.24
Earnings Per Share-0.22-0.20-0.52-1.18-0.97-2.23-6.95-16.25-10.18-11.80
Operating Cash Flow-7.18-0.41-13.18-19.89-13.35-25.41-19.94-29.55-24.49-15.09
Capital Expenditures-2.62-2.68-1.51-1.42-2.43-0.83-0.04-0.27-1.03-0.12
Free Cash Flow-9.80-3.09-14.69-21.31-15.77-26.24-19.98-29.82-25.52-15.21
Cash & Equivalents69.8182.9226.8622.9814.5830.348.0613.645.5319.12
Total Debt27.70-17.2410.130.070.11-0.040.080.31
Net Cash / Debt42.1082.929.6212.8514.5130.238.0613.605.4518.81
Assets15311954.5848.6034.3147.589.2215.187.7420.53
Liabilities42.1516.4632.0423.8912.1811.945.325.6720.715.75
Book Value11110222.5424.7122.1335.643.89-32.10-12.9714.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vericel Corporation
Country United States
Employees 241
CEO Dominick C. Colangelo

Stock Information

Ticker Symbol VCEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VCEL
IPO Date February 4, 1997

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.